Synthesis, in vivo antileukemic evaluation and comparative study of novel 5α-7-keto steroidal esters of chlorambucil and its active metabolite

In Vivo

Volumn 22, Issue 3, 2008, Pages 345-352

  Koutsourea, Anna I ^a   Fousteris, Manolis A ^a   Arsenou, Evagelia S ^a   Papageorgiou, Anthanasios ^b   Pairas, George N ^a   Nikolaropoulos, Sotiris S ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b Theagenion Anticance Institute   (Greece)

Author keywords

7 keto steroids; Antileukemic activity; Catalytic reduction; Chlorambucil; SAR; Steroidal esters

Indexed keywords

ACETIC ACID ETHYL ESTER; ANDROSTANE DERIVATIVE; CHLORAMBUCIL; CHLORAMBUCIL DERIVATIVE; CHLORMETHINE DERIVATIVE; HEXANE; METHANOL; SOLVENT;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL BOND; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IN VIVO STUDY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION;

EID: 45949092311     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Sienkiewicz P, Bielawski K, Bielawska A and Palka J: Inhibition of collagen and DNA biosynthesis by a povel amidine analogue of chlorambucil is accompanied by deregulation of β1-integrin and IGF-I receptor signaling in MDA-MB 231 cells. Environ Toxicol Pharmacol 20: 118-124, 2005.
2. Kryczka T, Kazimierczuk Z, Kozlowska, M, Chrapusta JS, Vilpo L, Vilpo J, Stachnik K, Janisz M and Grieb PB: Two novel nucleoside ester derivatives of chlorambucil as potential antileukemic prodrugs: a preliminary study. Anti-Cancer Drugs 18: 301-310, 2007.
3. IARC. Prednimustine. IARC Monogr Eval Carcinog Risks Hum 50: 115-122, 1990.
4. Tirelli U, Carbone A, Monfardini S and Zagonel V: A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute. Critical Rev Oncol Hematol 37: 153-158, 2001.
5. Bastholt L, Johansson C-J, Pfeiffer P, Svensson L, Johansson S-A, Gunnarsson PO and Mouridsen H: A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. Cancer Chemother Pharmacol 28: 205-210, 1991.
6. Yau CJ, Germond C, Gluck S, Cripps C, Verma S, Burns FB, Koski TM, Lister DC and Goss GD: Mitoxantrone, prednimustine, and vincristine for erderly patients with aggressive non-Hodgkin's lymphoma. Am J Hematol 59: 156-160, 1998.
7. Hillier MS, Marquis CJ, Zayas B, Wishnok SJ, Liberman GR, Skipper LP, Tannenbaum SR, Essigmann JM and Croy RG: DNA adducts by a novel antitumor agent 11β-dichloro in vitro and in vivo. Mol Cancer Ther 5: 977-994, 2006.
8. Marquis JC, Hillier SM, Dinaut AN, Rodrigues D, Mitra K, Essigmann JM and Croy RG: Disruption of gene expression and induction of apoptosis in prostate cancer cells by a DNA-damaging agent tethered to an androgen receptor ligand. Chem Biol 12: 779-787, 2005.
9. Katzenellenbogen AJ: Designing effective hybrid toxins. Chem Biol 12: 719-721, 2005.
10. Papageorgiou A, Koutsourea A, Arsenou E, Fousteris E, Mourelatos D and Nikolaropoulos S: Structure antileukemic activity relationship study of B- and D-ring modified and non-modified steroidal esters of chlorambucil's active metabolite. Anti-Cancer Drugs 16: 1075-1082, 2005.
11. Fousteris M, Koutsourea A, Arsenou E, Papageorgiou A, Mourelatos D and Nikolaropoulos S: Structure antileukemic activity relationship study of B- and D-ring modified and non-modified steroidal esters of chlorambucil. Anti-Cancer Drugs 17: 511-519, 2006.
12. Fousteris M, Koutsourea A, Arsenou E, Spyridonidou C, Mourelatos D and Nikolaropoulos S: Rational design, synthesis and in vitro evaluation of three new alkylating steroidal esters. Medicinal Chemistry 2: 569-576, 2006.
13. Fousteris M, Koutsourea A, Arsenou E, Papageorgiou A, Mourelatos D and Nikolaropoulos S: Structure antileukemic activity relationship study of B- and D-ring modified and non-modified steroidal esters of 4-methyl-3-N,N-bis(2-chloroethyl) amino benzoic acid (4-Me-CABA). A comparative study. Anti-Cancer Drugs 18: 997-1004, 2007.
14. Wall ME, Abernethy GS Jr, Caroll FJ and Taylor DJ: The effect of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems. J Med Chem 12: 810-818, 1969.
15. Catsoulacos P, Politis D and Wampler GL: A new steroidal alkylating agent with improved activity in advanced murine leukemias. Cancer Chemother Pharmacol 3: 67-70, 1979.
16. Catsoulacos P and Wampler GL: Activity of 30-hydroxy-13α-amino-13,17-seco-5α-androstan-17- oic-13,17-lactam- p-bis(2-chloroethyl)-aminophenylacetate. Oncology 39: 109-112, 1982.
17. Karayianni V, Mioglou E, Iakovidou Z, Mourelatos D, Fousteris M, Koutsourea A, Arsenou E and Nikolaropoulos S: A new approach for evaluating in vivo anti-leukemic activity using the SCE assay. An application on three newly synthesized anti-tumor steroidal esters. Mut Res 535: 79-86, 2003.
18. Fousteris MA, Koutsourea AI, Arsenou ES, Papageorgiou A, Mourelatos D and Nikolaropoulos S: Antileukemic and cytogenetic effects of modified and non-modified esteric steroidal derivatives of 4-methyl-3-bis(2-chloroethyl)amino benzoic acid (4-Me-CABA). Anticancer Res 22: 2293-2300, 2002.
19. Arsenou E, Fousteris M, Koutsourea A, Papageorgiou A, Karayianni V, Mioglou E, Iakovidou Z, Mourelatos D and Nikolaropoulos S: The allylic 7-ketone at the steroidal skeleton is crucial for the antileukemic potency of chlorambucil's active metabolite steroidal esters. Anti-Cancer Drugs 15: 983-990, 2004.
20. Karayianni V, Papageorgiou A, Mioglou E, Iakovidou Z, Mourelatos D, Fousteris M, Koutsourea A, Arsenou E and Nikolaropoulos S: 7-Keto hybrid steroidal esters of nitrogen mustard: cytogenetic and antineoplastic effects. Anti-Cancer Drugs 13: 637-643, 2002.
21. Goldin A, Sofina Z and Syrkin A: Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations. Natl Cancer Inst Monogr 55: 25-26, 1980.
22. Hanson RJ, Hunter AC and Roquier S: The preparation of some 13α-androstanes. Coll Czech Chem Comm 63: 1646-1654, 1998.
23. 5-7-ketones. Pol J Chem 53: 453-459, 1979.
24. Jones SR, Selinsky BS, Rao MN, Zhang X, Kinney WA and Tham FS: Efficient route to 7α-(benzoyloxy)-3-dioxolane cholestan-24 (R)-ol, a key intermediate in the synthesis of squalamine. J Org Chem 63: 3786-3789, 1998.
25. Choucair B, Dherbomez M, Roussakis C and Kihel L: Synthesis of spermidinylcholestanol and spermidinylcholesterol, squalamine analogues. Tetrahedron 60: 11477-11486, 2004.
26. Schmidt WA, Doert T, Goutal S, Gruner M, Mende F, Kurzchalia VT and Knölker H-J: Regio- and stereospecific synthesis of cholesterol derivatives and their hormonal activity in Caenorhabditis elegans. Eur J Org Chem 16: 3687-3706, 2006.
27. Okumura Y, Nakamura Y, Takeuchi I, Kato I, Fujimoto Y and Ikekawa N: Formal synthesis of squalamine from desmosterol. Chem Pharm Bull 51: 117-1182, 2003.
28. Krafft M, Dasse O and Fu Z: Synthesis of the C/D/E and A/B rings of xestobergsterol-(A). J Org Chem 64: 2475-2485, 1999.
29. Kim H, Choi B, Kwon K, Lee S, Kwak H and Lee C: Synthesis and antimicrobial activity of squalamine analogue. Bioorg Med Chem 8: 2059-2065, 2000.
30. 7-6-ketosteroids in the presence of sodium nitrite. Tetrahedron 58: 6033-6037, 2002.
31. Rao HSP: Capping drugs: development of prodrugs. Resonance 19-27, 2003. Internet publication: http://www.ias.ac.in/resonance/Feb2003/pdf/ Feb2003p19-27.pdf.
32. Bersch B: The pharmacokinetic model and disruption pattern of new sexual-steroid-hormone-linked anticancer drugs. J Cancer Res Clin Oncol 116: 467-469, 1990.
33. Kouloumenta A, Stephanou G, Demopoulos NA and Nikolaropoulos SS: Genetic effects caused by potent antileukemic steroidal esters of chlorambucil's active metabolite. Anticancer Drugs 16: 67-75, 2005.
34. Sharma U, Marquis JC, Dinaut N, Hillier SM, Fedeles B, Rye PT, Essigmann JM and Croy RG: Design, synthesis and evaluation of estradiol-linked genotoxicants as anti-cancer agents. Biorg Med Chem Let 14: 3829-3833, 2004.
35. Rink SM, Yarema KJ, Solomon MS, Paige LA, Tadayoni-Rebek BM, Essigmann JM and Croy RG: Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Proc Natl Acad Sci USA 93: 15063-15068, 1996.
36. Mitra K, Marquis JC, Hillier SM, Rye PT, Zayas B, Lee AS, Essigmann JM and Croy RG: A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells. JACS 124: 1862-1863, 2002.
37. Freeman MR, Cinar B, Kim J, Mukhopadhyay N, Di Vizio D, Adam R and Solomon K: Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids 72: 210-217, 2007.
38. Wehling M and Losel R: Non-genomic steroid hormone effects: membrane or intracellular receptors? J Steroid Biochem Mol Biol 102: 180-183, 2006.
39. Joska J and Fajkos J: Steroids. LVIII. Some 7-substituted analogs of androgens. Coll Czech Chem Commun 26: 1646-1657, 1961.
40. Marwah P, Marwah A and Lardy AH: Microwave-induced selective enolization of steroidal ketones and efficient acetylation of sterols in semisolid state. Tetrahedron 59: 2273-2287, 2003.
41. Lardy H, Kneer N, Wei Y, Patridge B and Marwah P: Ergosteroids II: biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids 63: 158-165, 1998.